259 related articles for article (PubMed ID: 22899627)
61. First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.
Schroeder T; Kobbe G
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1703-4. PubMed ID: 26277403
[No Abstract] [Full Text] [Related]
62. [Treatment of MDS].
Usuki K
Rinsho Ketsueki; 2014 Oct; 55(10):1882-92. PubMed ID: 25297752
[No Abstract] [Full Text] [Related]
63. Improving AML Classification Using Splicing Signatures.
Bowman TV
Clin Cancer Res; 2020 Jul; 26(14):3503-3504. PubMed ID: 32317289
[TBL] [Abstract][Full Text] [Related]
64. Review: recent clinical trials in epigenetic therapy.
Oki Y; Issa JP
Rev Recent Clin Trials; 2006 May; 1(2):169-82. PubMed ID: 18473969
[TBL] [Abstract][Full Text] [Related]
65. Drug therapy for myelodysplastic syndrome: building evidence for action.
Tefferi A; Letendre L
Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
[No Abstract] [Full Text] [Related]
66. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
67. Myelodysplastic syndromes--many new drugs, little therapeutic progress.
Tefferi A
Mayo Clin Proc; 2010 Nov; 85(11):1042-5. PubMed ID: 20861462
[No Abstract] [Full Text] [Related]
68. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
[TBL] [Abstract][Full Text] [Related]
69. MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia.
Krejcik Z; Belickova M; Hrustincova A; Votavova H; Jonasova A; Cermak J; Dyr JE; Merkerova MD
Cancer Biomark; 2018; 22(1):101-110. PubMed ID: 29630523
[TBL] [Abstract][Full Text] [Related]
70. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
[No Abstract] [Full Text] [Related]
71. Hypomethylating agents in myelodysplastic syndromes.
Blum WG
Clin Adv Hematol Oncol; 2011 Feb; 9(2):123, 126-8. PubMed ID: 22379662
[No Abstract] [Full Text] [Related]
72. It dices, it splices!
Klimek VM
Blood; 2011 Dec; 118(24):6237-8. PubMed ID: 22161850
[No Abstract] [Full Text] [Related]
73. Recent advances in myelodysplastic syndromes.
Shadduck RK; Latsko JM; Rossetti JM; Haq B; Abdulhaq H
Exp Hematol; 2007 Apr; 35(4 Suppl 1):137-43. PubMed ID: 17379099
[TBL] [Abstract][Full Text] [Related]
74. [Pathogenesis of and therapeutic progress for myelodysplastic syndromes].
Miyazawa K
Rinsho Ketsueki; 2008 Oct; 49(10):1358-67. PubMed ID: 18833920
[No Abstract] [Full Text] [Related]
75. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Taylor J; Lee SC
Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
[TBL] [Abstract][Full Text] [Related]
76. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype.
Scherman E; Malak S; Perot C; Gorin NC; Rubio MT; Isnard F
Leukemia; 2012 Apr; 26(4):822-4. PubMed ID: 21997572
[No Abstract] [Full Text] [Related]
77. Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.
Figg JW; Barajas JM; Obeng EA
Curr Opin Hematol; 2021 Mar; 28(2):73-79. PubMed ID: 33492002
[TBL] [Abstract][Full Text] [Related]
78. How I treat patients with myelodysplastic syndromes.
Stone RM
Blood; 2009 Jun; 113(25):6296-303. PubMed ID: 19383969
[No Abstract] [Full Text] [Related]
79. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
Ørskov AD; Grønbæk K
Cancer J; 2017; 23(5):277-285. PubMed ID: 28926428
[TBL] [Abstract][Full Text] [Related]
80. Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.
Steensma DP; Porcher JC; Litzow MR; Hogan WJ; Arora S; Van Laar ES
Leuk Res; 2009 Jul; 33(7):e81-2. PubMed ID: 19157545
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]